SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (156)9/11/1997 5:41:00 PM
From: JOSEPH VON MEISTER   of 1826
 
SALAGEN'S MARKET POTENTIAL IS 1 IN 1,250 WOMEN FOR PRIMARY SJOGRENS; IN CANADA THAT'S 25 MIL/2 (ASSUMING 1/2 WOMEN) SO 12.5 MIL / 1,250 OR 10,000 PATIENTS AT US$1,000 PER YEAR TO THE COMPANY. THE US MARKET IS ROUGHLY 10 TIMES THE SIZE OF CANADA. SUBSTANTIALLY GREATER PATIENT COUNT FOR SECONDARY SJOGRENS, DRY EYE, PHARMACEUTICALLY CAUSED DRY MOUTH, ETC.

JVM
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News